Race Oncology is an ASX listed precision oncology company with a Phase II/III cancer drug called Bisantrene

Bisantrene is a potent small molecule inhibitor of the Fat mass and obesity associated (FTO) protein. Over-expression of FTO has been shown to be an important to the progression of a wide range of cancers. Race Oncology is first exploring the use of Bisantrene as a new therapy for melanoma and clear cell renal cell carcinoma (kidney cancer), which are both frequent FTO-driven cancers.

The Company also has compelling clinical data for the use of Bisantrene as a chemotherapeutic agent with reduced cardiotoxicity in Acute Myeloid Leukaemia (AML), Breast and Ovarian cancers and is investigating its use in these areas.

Race is pursuing outsized commercial returns for shareholders via its ‘Three Pillar’ strategy for the clinical development of Bisantrene.

Review our plans under the Three Pillar strategy via our 2020 strategic update which was released to the ASX on 30 November 2020.

Race is led by a seasoned team and Board, supported by a network of key opinion leaders and collaborators. See our leadership team here.



The ‘new’ Race launched with the announcement of the Three Pillar Strategy


5-Path Strategy announced advancing Biantrene in AML, Breast and Ovarian Cancers,


Race Oncology lists on the ASX (RAC) with the mission to rescue Bisantrene and return it to the clinic.


Bisantrene rediscovered, new patents filed and orphan drug designation obtained.


Bisantrene was approved for marketing in France for the treatment of AML. Further Bisantrene development stopped after issues with the Phase III Breast Cancer trial design.


More than 40 published clinical trials run assess its efficacy and safety in a wide range of cancers including leukemias, breast and ovarian. The studies covered more than 2,000 treated patients and revealed that Bisantrene was shown to possess low cardiotoxicity potential and useful therapeutic efficacy in several cancers, notably AML, Breast and Ovarian.


Bisantrene discovered in the pharmaceutical company Lederle Laboratories.